Al-Ola Abdallah, Board Member at Kansas Society OF Clinical Oncology, Associate Professor Of Medicine, Assistant Professor at University of Kansas Medical Center, shared a post on X:
“Session 2 at ICET 2026.
Bispecific antibodies are redefining the MM landscape!
Prerna Mewawalla, MD (Allegheny Health System) highlights the power of Teclistamab, Elranatamab and next-gen BsAbs-bringing deep responses in heavily pretreated disease with evolving safety profiles.
‘Beyond BCMA‘ strategies on the horizon.”
Other articles featuring Al-Ola Abdallah on OncoDaily.
